Onco-Innovations Engages Nanosoft to Advance ONC010 Development Program

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has entered into a services agreement with Nanosoft Polymers to support the development of ONC010, the company's lead nanoparticle-formulated PNKP inhibitor. The collaboration aims to strengthen the manufacturing and formulation foundation of ONC010, which targets solid tumors through a patented technology platform.

Under the agreement, Nanosoft will provide polymer process development, analytical characterization, formulation optimization, scale-up support, and technology transfer services for Onco's proprietary PEO-PBCL polymer platform. These activities are critical as the program advances through IND-enabling development and preparation for future clinical studies. The partnership is designed to establish scalable polymer production processes, enhance analytical methods, and support future GMP manufacturing readiness.

Nanosoft's work will complement ongoing chemistry, manufacturing, and controls (CMC) activities with Dalton Pharma Services and preclinical development efforts at Nucro-Technics. Together, these collaborations position Onco-Innovations to advance ONC010 toward first-in-human clinical evaluation. The company has secured an exclusive worldwide license to patented technology targeting solid tumors, underscoring its commitment to innovative cancer treatments.

Investors can find the latest news and updates regarding ONNVF in the company's newsroom at https://ibn.fm/ONNVF. The full press release is available at https://ibn.fm/djEgt.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Its mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company's focus on nanoparticle drug delivery systems represents a promising approach to improving therapeutic outcomes for cancer patients.

The engagement of Nanosoft Polymers marks a significant step in Onco-Innovations' development pipeline. By addressing key manufacturing and formulation challenges early, the company aims to streamline the path to clinical trials and eventual commercialization. This collaboration highlights the importance of strategic partnerships in the biotechnology sector, where specialized expertise can accelerate drug development timelines.